Jason Litten - 02 Jan 2026 Form 4 Insider Report for GENELUX Corp (GNLX)

Reporting relationship: Chief Medical Officer
Issuer ticker: GNLX
Reported as of: 02 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Jan 2026, 17:32:02 UTC
Source filing: View source filing
Reporting owner signature: /s/ Eric Groen, Attorney-in-Fact

Key filing fact

Jason Litten filed Form 4 for GENELUX Corp (GNLX) on 07 Jan 2026.

Key facts

This page summarizes Jason Litten's Form 4 filing for GENELUX Corp (GNLX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 07 Jan 2026, 17:32.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001909400 Primary reporting owner

Litten Jason

Relationship: Chief Medical Officer
Address: C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Signature: /s/ Eric Groen, Attorney-in-Fact
Signature date: 07 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GNLX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +275,000
Change %
Price: $0.000000
Shares after: 275,000
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 275,000
Exercise price: $4.55
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option will vest 25% on the first anniversary of the grant date, and the remaining shares will vest in 36 equal monthly installments thereafter.